Literature DB >> 34076373

Prevalence of candidiasis and oral candidiasis in COVID-19 patients: a cross-sectional pilot study from the patients' registry in a large health center.

Joseph Katz.   

Abstract

OBJECTIVE: Candida albicans in considered to be a marker of immunosuppression in serious chronic condition such as HIV and cancer patients on immunosuppresion medications. The new COVID-19 pandemic has caused acute respiratory distress syndrome in many patients, which poses a risk of super-infections including Candida strains causing oral candidiasis as well as invasive fungal infections. The aim of the study was to examine the association between COVID-19 and oral and general candidiasis. METHOD AND MATERIALS: The i2b2 data repository platform was used to analyze the interrelations between COVID-19, oral candidiasis, and total candidiasis in a hospital population. ICD diagnoses codes were used to generate queries on total numbers and demographic data on COVID-19, oral candidasis, total candidasis, and COVID-19 with each form of candidasis.
RESULTS: From the 889 patients diagnosed with COVID-19, 106 (12%) were diagnosed with candidiasis at large and 14 (1.6%) had oral candidiasis. The odds ratio (OR) for COVID-19 in the presence of oral candidiasis was 2.01 (95% CI 1.1870 to 3.4143, P = .094) and the OR for COVID-19 in the presence of candidiasis was 3.73 (95% CI 3.0419 to 4.5847, P < .0001 ). African American were disproportionally affected and comprised about 40% of the COVID-19/candidiasis groups.
CONCLUSIONS: Total candidiasis was significantly associated with increased risk for COVID-19, whereas oral candidiasis showed an insignificant trend. The dental practitioner should be aware of the importance of unexplained oral and systemic candidiasis as a potential harbinger of T and B cell immunosuppression associated with viral in-fections. COVID-19 may be a risk factor for total candidiasis.

Entities:  

Keywords:  COVID-19; candidiasis; odds ratio; oral candidiasis; thrush

Year:  2021        PMID: 34076373     DOI: 10.3290/j.qi.b1491959

Source DB:  PubMed          Journal:  Quintessence Int        ISSN: 0033-6572            Impact factor:   1.677


  5 in total

1.  COVID-19-associated fungal infections in Iran: A systematic review.

Authors:  Tina Nazari; Fatemeh Sadeghi; Alireza Izadi; Setayesh Sameni; Shahram Mahmoudi
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

2.  Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates from a Hospital in Slovakia.

Authors:  Lucia Černáková; Anna Líšková; Libuša Lengyelová; Célia F Rodrigues
Journal:  Medicina (Kaunas)       Date:  2022-04-22       Impact factor: 2.948

3.  Potency of phytosynthesized silver nanoparticles from Lathraea squamaria as anticandidal agent and wheat seeds germination enhancer.

Authors:  Oleksandr Smirnov; Vitalii Kalynovskyi; Yuliia Yumyna; Pavlina Zelena; Tetiana Levenets; Mariia Kovalenko; Volodymyr Dzhagan; Mykola Skoryk
Journal:  Biologia (Bratisl)       Date:  2022-05-18       Impact factor: 1.653

Review 4.  Fungal Colonization and Infections-Interactions with Other Human Diseases.

Authors:  Shanmuga S Mahalingam; Sangeetha Jayaraman; Pushpa Pandiyan
Journal:  Pathogens       Date:  2022-02-06

5.  Exploring SARS-CoV2 host-pathogen interactions and associated fungal infections cross-talk: Screening of targets and understanding pathogenesis.

Authors:  Abdul Arif Khan; Sudhir K Jain; Mahendra Rai; Samiran Panda
Journal:  Comput Struct Biotechnol J       Date:  2022-08-10       Impact factor: 6.155

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.